DAPAGLIFLOZIN WITH SITAGLIPTIN

Brand name:

• Sidapvia®

Pharmaceutical company:

AstraZeneca Pty Ltd

Condition/indication:
(therapeutic use)

• Type 2 diabetes mellitus

PBAC Submission type:

New PBS listing (Category 2)

Comment:

--

Public Summary Document:

Not yet available

Related medicines:

--

Submission received for:

March 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 13/03/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

14/05/2024

Lodgement of required documentation:

03/06/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 12/06/2024

Status:

Finalised

Government processes:

Commenced on 20/08/2024

Medicine listed on the PBS:

01/11/2024 (see PBS schedule)

---